Abstract
Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.
Original language | English (US) |
---|---|
Title of host publication | Kucers the Use of Antibiotics |
Subtitle of host publication | A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition |
Publisher | CRC Press |
Pages | 2550-2558 |
Number of pages | 9 |
ISBN (Electronic) | 9781498747967 |
ISBN (Print) | 9781498747950 |
DOIs | |
State | Published - Jan 1 2017 |
ASJC Scopus subject areas
- General Medicine
- Pharmacology, Toxicology and Pharmaceutics(all)